Five-Years Tigecycline Experience an Analysis of Real-Life Data

Aim: Tigecycline has been approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections, skin and soft tissue infections and community-acquired pneumonia. In our study, we examined the efficacy of tigecycline in clinical practice and reported real life data from our hospital over a period of five years. Methods: The study was conducted between 2008 and 2013 on patients who received tigecycline for longer than 48 hours in Ankara Training and Research Hospital. Clinical success was defined as clinical recovery and microbiological cure in patients who used tigecycline. Any reason for discontinuation of tigecycline treatment was considered a clinical failure. Results: In our hospital, 320 patients were administered tigecycline between 2008 and 2013. Tigecycline was mainly used for pneumonia and skin and soft tissue infections. Tigecycline was used as monotherapy in 174 patients (54.1%). The most frequently isolated agent in tigecycline-treated patients was Acinetobacter baumannii (43.4%) followed by Enterococcus (6.9%). A change in treatment was not considered necessary in 243 (75.9%) patients who received tigecycline, while it was changed in 77 patients (24.1%). Conclusion: In conclusion, the use of tigecycline can be an effective treatment choice, either as monotherapy or as a combination antibiotic therapy

Türkiye'ye İnternetin gelişi ve ilk kullanım alanları

Ankara : İhsan Doğramacı Bilkent Üniversitesi İktisadi, İdari ve Sosyal Bilimler Fakültesi, Tarih Bölümü, 2012.This work is a student project of the The Department of History, Faculty of Economics, Administrative and Social Sciences, İhsan Doğramacı Bilkent University.by Selim Tezcan.Tezcan, Selim. HIST 203-05TEZCAN HIST 203-05/3 2011-1

The Effect of Clinical, Laboratory and Radiological Findings on Mortality in Patients with Severe COVID-19

Introduction: COVID-19 can range from asymptomatic to critical illness and may result in mortality. In our study, we aimed to evaluate the effect of clinical, laboratory, and radiological findings on mortality in patients diagnosed with severe COVID-19. Materials and Methods: We included SARS-CoV-2 polymerase chain reaction (PCR) positive patients followed up in infectious diseases pandemic and chest diseases pandemic departments at Rize State Hospital in 01.01.2020-31.03.2021. Epidemiological data, chronic diseases, admission symptoms, laboratory findings, and radiological findings of the patients were recorded retrospectively from the patient files. Patients were grouped as survivors and non-survivors. We defined severe disease as patients with pneumonia on radiological imaging, oxygen saturation < 0.05. Results: 135 patients, 110 of whom were survivors and 25 non-survivors, were included in the study. The mean age was 65.5 ± 15.45 years and 61.5% (n= 83) of patients were male. The mean age of the non-survivors was higher compared to survivors (p= 0.007). The mortality rates in patients with coronary artery disease (CAD) and chronic kidney disease (CKD) were statistically higher in non-survivors (p= 0.032, p= 0.032). The rate of tachypnea was found to be statistically higher in the non-survivors (p= 0.001). During the follow-up period, chest X-rays were taken every other day for assessment. The rate of progression was found to be statistically significantly higher in non-survivors (p= 0.004). According to the results of the multivariate logistic regression analysis, the presence of CAD, tachypnea at hospital admission, and progression in chest X-ray were considered independent risk factors for mortality. Conclusion: In this study, the factors that may worsen the disease in the severe COVID-19 disease course were estimated and the presence of CAD, tachypnea, and progression in chest X-ray was found to be independent risk factors for mortality. In addition to chronic diseases and symptoms at presentation, the detection of progression in chest X-ray in the clinical follow-up of patients is a risk factor for mortality, which shows us that radiological follow-up should be kept in mind during the course of the disease

A Case of Enterobacter cloacae Meningitis Secondary to Urinary Tract Infection

Gram-negatif bakterilere bağlı menenjit, genellikle yenidoğanlarda ve yaşlı hastalarda, prostat biyopsisi, beyin cerrahisi gibi girişimlerden sonra veya kafa travmasından sonra gelişebilmektedir. Bu hastalarda akut bakteriyel menenjitin ateş, baş ağrısı ve meninks iritasyonu gibi tipik bulguları görülmeyebilmektedir ve mortalitesi yüksektir. Bu yazıda üriner sistem infeksiyonuna bağlı bakteriyemiye sekonder geliştiği düşünülen bir Gram-negatif bakteri menenjiti olgusu sunulmuştur. Uygun antibiyotik tedavisine rağmen hasta eksitus olmuştur. Özellikle yaşlı ve komorbid hastalığı olan hastalar antibiyotik tedavisine yanıt vermediğinde ve bilinç bozukluğu geliştiğinde santral sinir sistemi infeksiyonu mutlaka akılda tutulmalıdır.Gram-negative bacterial meningitis can usually be seen in neonates and elderly patients, after head trauma or interventions such as prostate biopsy and brain surgery. Typical findings of acute bacterial meningitis such as fever, headache and meningeal irritation signs may not be observed, and mortality rate is high in these patients. In this report, we present a case of Gramnegative bacterial meningitis secondary to bacteremia probably due to urinary tract infection. The patient died despite appropriate antibiotic therapy. Central nervous system infection should be kept in mind especially when elderly patients with comorbid diseases do not respond to antibiotic treatment and changes in mental status develop

Five-Years Tigecycline Experience an Analysis of Real-Life Data

WOS: 000437086400007Aim: Tigecycline has been approved by the Food and Drug Administration for the treatment of complicated intra-abdominal infections, skin and soft tissue infections and community-acquired pneumonia. In our study, we examined the efficacy of tigecycline in clinical practice and reported real life data from our hospital over a period of five years. Methods: The study was conducted between 2008 and 2013 on patients who received tigecycline for longer than 48 hours in Ankara Training and Research Hospital. Clinical success was defined as clinical recovery and microbiological cure in patients who used tigecycline. Any reason for discontinuation of tigecycline treatment was considered a clinical failure. Results: In our hospital, 320 patients were administered tigecycline between 2008 and 2013. Tigecycline was mainly used for pneumonia and skin and soft tissue infections. Tigecycline was used as monotherapy in 174 patients (54.1%). The most frequently isolated agent in tigecycline-treated patients was Acinetobacter baumannii (43.4%) followed by Enterococcus (6.9%). A change in treatment was not considered necessary in 243 (75.9%) patients who received tigecycline, while it was changed in 77 patients (24.1%). Conclusion: In conclusion, the use of tigecycline can be an effective treatment choice, either as monotherapy or as a combination antibiotic therapy

A Case of Enterobacter cloacae Meningitis Secondary to Urinary Tract Infection

WOS: 000464106200018Gram-negative bacterial meningitis can usually be seen in neonates and elderly patients, after head trauma or interventions such as prostate biopsy and brain surgery. Typical findings of acute bacterial meningitis such as fever, headache and meningeal irritation signs may not be observed, and mortality rate is high in these patients. In this report, we present a case of Gram-negative bacterial meningitis secondary to bacteremia probably due to urinary tract infection. The patient died despite appropriate antibiotic therapy. Central nervous system infection should be kept in mind especially when elderly patients with comorbid diseases do not respond to antibiotic treatment and changes in mental status develop